Tag: Cornel

Local Charity Aims To Cure Deadly Pediatric Cancer With Star Power


 

We love great non-for-profit work, for the eighth year in a row, New York City-based not-for-profit 501(c)(3) The Cristian Rivera Foundation is gathering celebrities, supporters and donors to raise money toward a groundbreaking clinical trial aimed at curing Diffuse Intrinsic Pontine Glioma (DIPG).

The eighth annual Cristian Rivera Foundation Celebrity Gala will be held at Broad Street Ballroom in Manhattan on Wednesday, November 30. The foundation namesake Cristian Rivera was only 4 years old when he was diagnosed with the rare pediatric brain stem tumor, which generally affects children between the ages of 1 and 9. Approximately 200 children are diagnosed with DIPG each year in the United States and most only survive for 3 to 18 months after diagnosis.

Through auction items, ticket sales and more, the eighth annual Cristian Rivera Foundation Celebrity Gala will raise money in support of a clinical trial at Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College that officially got underway on May 1, 2012, thanks to the more than $700,000 in donations from the

Cristian Rivera Foundation to date. Spearheaded by Dr. Mark Souweidane, the Director of the Weill Cornell Pediatric Brain and Spine Center, this trial is the first of its kind to use convection-enhanced delivery to administer radio immunotherapy to children with an otherwise incurable tumor.Dr. Souweidane has found a way to operate on a tumor that had, until now, been deemed inoperable. Dr. Souweidane has developed a safe method for drug delivery to these tumors by a highly innovative surgical procedure. Up until this time surgery has played no role in the treatment plan for these children with DIPG. This procedure involves implanting a small hair-like device into the center of the tumor and then using a slow constant flow of drug directly into the involved brain stem. The Cristian Rivera Foundation is proud to support Dr. Souweidane’s important research.

The eighth annual Cristian Rivera Foundation Celebrity Gala will be hosted by Cristian Rivera Foundation Board of Director and Anchor of the award winning NBC’s “Today in New York”, Darlene Rodriguez. The event kicks off at 6pm with red carpet arrivals from esteemed guests and foundation committee members. Tickets are sold out and include passed hors d’oeuvres, five hours of open bar, and dinner provided by Celebrity Chefs Alex Garcia, a committee member of the Cristian Rivera Foundation. There will also be live and silent auctions offering one-of-a-kind items and experiences.

The eighth annual Cristian Rivera Foundation Celebrity Gala will begin at 6 PM and end at 11 PM on Wednesday, November 30th. The Broad Street Ballroom is located at 41 Broad Street in the Financial District. Sponsorship packages and ads to be displayed in the program are still available for purchase. The Cristian Rivera Foundation is accepting donations in the fight against DIPG. All contributions are tax-deductible and critical to finding a cure for this disease and assisting children and families in their ongoing fight against DIPG.

Follow here to read more

 

 

Dr. Souweidane Treats Final Patient in Groundbreaking DIPG Clinical Trial

marksw

 

Dr. Mark Souweidane today treated the final patient in his Phase I clinical trial of convection-enhanced delivery (CED) for diffuse intrinsic pontine glioma (DIPG). The trial, which had enrolled 31 patients over the past four years, was designed to test the safety of CED as a means of delivering a cancer-fighting drug directly to the site of a DIPG tumor. (More about the DIPG trial.)

The trial received FDA approval in late 2011, and the first patient was treated in May 2012. (Read “Cheering for Caitlin,” a profile of the first patient.) Since then, 30 children have received infusions of a therapeutic agent called 124I-8H9, which consists of the 8H9 antibody (produced by mice and effective against many kinds of tumors) combined with the radioactive substance 124I. The dosage of the drug was increased over the course of the trial, also testing safety, but no dose-limiting side effects occurred in any patient.

The infusions, which were done at Memorial Sloan Kettering Cancer Center, were able to deliver the drug directly to the brain stem tumor and were not blocked by the body’s protective blood-brain barrier, which normally prevents chemotherapy drugs from crossing from the bloodstream into the brain in sufficient concentrations to attack a tumor. In this trial, Dr. Souweidane was able to achieve concentrations of 1,000 times or more than what can be achieved with IV chemotherapy. He was also able to design and test new ways to measure those concentrations at the tumor site and monitor how long the drug stayed in the tumor.

Dr. Souweidane and his team will spend the next several months evaluating the data and preparing the results for publication. In the meantime, researchers in the Children’s Brain Tumor Project laboratory have been working to pave the road for the next stages of the trial. Other drugs and drug combinations are being tested to determine what the best agents are to infuse, and at what dose levels. DIPG cell lines are also being grown in the lab, providing a rich source of information about how the tumor mutates over time and responds to different treatments in vitro as well as in animal models. (More about the Children’s Brain Tumor Project.)

Read the blog post written by Dr. Souweidane after he treated the final patient in the trial, click the link below www.weillcornellbrainandspine.org/dipg-new-beginning